Cervomed Q2 FY26 net loss widens 5% to $6.57 million; revenue turns to none - CRVO News | RalliesCervomed Q2 FY26 net loss widens 5% to $6.57 million; revenue turns to none
C
CRVO• Cervomed reports wider Q2 loss and no grant revenue
- Cervomed posted a net loss of $6.57 million in Q2, widening 5% from the prior-year quarter.
- Operating loss was $6.68 million, up 1%, as no grant revenue was recognized versus $1.76 million a year earlier.
- Total operating expenses fell 20% to $6.68 million, with R&D down 15% to $4.32 million and G&A down 28% to $2.36 million.
- Cash, cash equivalents, and marketable securities totaled about $24.9 million at June 30, 2026; liquidity runway projected through Q3 2027.
- June financings raised about $20.5 million gross; strategic priority set to secure a partner to advance neflamapimod into Phase 3 in DLB.
•
